Sorrento Therapeutics (SRNE) Stock Price, News & Analysis

Company Overview

Sorrento Therapeutics, Inc. was a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company historically focused on developing therapies for cancer, chronic pain, autoimmune disease and infectious diseases, using technologies involving antibodies, cellular therapies and targeted drug delivery.

Its oncology programs included antibody-drug conjugates, immunotherapies and other targeted treatments, while its pain portfolio included resiniferatoxin-based therapies and products developed through its Scilex subsidiary. Sorrento also developed the Sofusa lymphatic drug-delivery platform and pursued treatments and diagnostic products related to COVID-19, including COVISTIX and COVI-DROPS. Several of these programs remained investigational or were managed through subsidiaries and strategic partners.

Founded in 2006, Sorrento operated primarily in the United States and conducted research and clinical-development activities involving international partners. Henry Ji served as the company’s longtime chairman and chief executive officer. Sorrento filed for Chapter 11 bankruptcy protection in 2023, after which its corporate assets and business operations were subject to restructuring and legal proceedings. Accordingly, historical descriptions of the company and its development pipeline may not reflect its status following the bankruptcy process.

Key Stats

• Today's Range: $0.0008 to $0.0008
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.05
• Volume: 4,586 shs
• Average Volume: 251,786 shs
• Market Capitalization: $441.02 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 9/25/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SRNE
• CIK: 850261
• Web: www.sorrentotherapeutics.com
• Phone: (858) 203-4100
• Fax: 858-210-3759
• Employees: 949
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $60.32 million
• Price / Sales: 0.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 551,280,000
• Free Float: 536,948,000
• Market Cap: $441.02 thousand
• Optionable: No Data
• Beta: 0.11